Investigating the Effects of Atezolizumab in People Whose Tumour DNA or RNA Indicates Possible Sensitivity

This study will investigate the effects of atezolizumab on select cancer types in people whose analysis of tumour DNA and RNA indicates they may be sensitive to atezolizumab. This study aims to determine if the information from the cancer genome analysis corresponds with the effects of atezolizumab on individuals and their cancer. This is a Phase 2 study, which is undertaken after preliminary safety testing on a drug is completed, and will involve approximately 200 participants. Participants are assigned to one of 8 cohorts based on their primary tumour type: breast, lung, gastrointestinal (G

Trial Details

NCT ID

NCT04273061

Phase

PHASE2

Sponsor

British Columbia Cancer Agency

Status

RECRUITING

Cancer Type

Lung Cancer

Interventions

Atezolizumab

Locations (sample)

Vancouver, British Columbia, Canada|49.24966,-123.11934
Toronto, Ontario, Canada|43.70643,-79.39864

Key Eligibility Criteria

Age greater than or equal to 18 years at the time of signature of informed consent.
Participants with an incurable solid tumour who have undergone whole genome and transcriptome analysis (WGTA) as part of Personalized OncoGenomics …
a. Participants must have had successful sequencing of their tumour, been formally reviewed by the POG (or POG-approved) genome analysts and found …
Eastern Cooperative Oncology Group (ECOG) performance status 0-2.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lung Cancer Trials on Trialify →